Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CREBBP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CREBBP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CREBBP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CREBBP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CREBBP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CREBBP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CREBBP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CREBBP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CREBBP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CREBBP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
GO:003164710 | Cervix | CC | regulation of protein stability | 63/2311 | 298/18723 | 1.14e-05 | 2.45e-04 | 63 |
GO:003460510 | Cervix | CC | cellular response to heat | 22/2311 | 69/18723 | 1.65e-05 | 3.20e-04 | 22 |
GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:000166610 | Cervix | CC | response to hypoxia | 61/2311 | 307/18723 | 1.04e-04 | 1.34e-03 | 61 |
GO:007048210 | Cervix | CC | response to oxygen levels | 67/2311 | 347/18723 | 1.21e-04 | 1.51e-03 | 67 |
GO:00714786 | Cervix | CC | cellular response to radiation | 41/2311 | 186/18723 | 1.41e-04 | 1.71e-03 | 41 |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:003629310 | Cervix | CC | response to decreased oxygen levels | 62/2311 | 322/18723 | 2.29e-04 | 2.57e-03 | 62 |
GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
GO:00094089 | Cervix | CC | response to heat | 27/2311 | 110/18723 | 3.12e-04 | 3.32e-03 | 27 |
GO:00022183 | Cervix | CC | activation of innate immune response | 16/2311 | 52/18723 | 3.61e-04 | 3.75e-03 | 16 |
GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CREBBP | SNV | Missense_Mutation | novel | c.4586N>T | p.Asp1529Val | p.D1529V | Q92793 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.1598N>T | p.Ala533Val | p.A533V | Q92793 | protein_coding | tolerated(0.13) | possibly_damaging(0.719) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.5272N>A | p.Glu1758Lys | p.E1758K | Q92793 | protein_coding | tolerated(0.43) | benign(0.169) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | rs559939930 | c.3883N>A | p.Val1295Ile | p.V1295I | Q92793 | protein_coding | deleterious(0.01) | possibly_damaging(0.599) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | | c.2140N>A | p.Arg714Ser | p.R714S | Q92793 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.1802N>A | p.Arg601Gln | p.R601Q | Q92793 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.740N>A | p.Ser247Tyr | p.S247Y | Q92793 | protein_coding | deleterious(0.01) | possibly_damaging(0.887) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.347N>T | p.Ser116Ile | p.S116I | Q92793 | protein_coding | deleterious_low_confidence(0.01) | benign(0.403) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | | c.775G>A | p.Ala259Thr | p.A259T | Q92793 | protein_coding | tolerated(0.2) | possibly_damaging(0.801) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.5642N>A | p.Ser1881Asn | p.S1881N | Q92793 | protein_coding | tolerated(0.16) | benign(0.264) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | (-)-ROLIPRAM | (-)-ROLIPRAM | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | ETAZOLATE | ETAZOLATE | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | TRIAZOLAM | TRIAZOLAM | 22137933 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | DNDI1417457 | CHEMBL1530911 | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | ESTAZOLAM | ESTAZOLAM | 22137933 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLMALONATE | CHEMBL1797712 | 21292492 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | PAPAVERINE | PAPAVERINE | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | C 82 | | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | PRI-724 | PRI-724 | |